Nanjing, China

Ying Tang

This inventor holds 1 USPTO granted patent. Top assignee: Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ying Tang. Retrieved from https://idiyas.com/inventor/ying-tang-r0cy83eo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ying Tang: Innovator in Pharmaceutical Composition

Introduction

Ying Tang is a notable inventor based in Nanjing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug compositions. His work focuses on enhancing the efficacy of treatments through precise formulations.

Latest Patents

Ying Tang holds 1 patent for a unit dosage composition of an AKT inhibitor. This patent specifically relates to a pharmaceutical composition in unit dosage form that includes a compound of formula I-0 or a pharmaceutically acceptable salt thereof. The formulation is designed to contain a mass of the compound I-0 or its salt ranging from 5 mg to 400 mg, calculated as free base.

Career Highlights

Ying Tang is currently employed at Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. His role at this esteemed company allows him to engage in cutting-edge research and development in the pharmaceutical industry. His innovative approach has positioned him as a key player in the advancement of drug formulations.

Collaborations

Ying Tang collaborates with talented professionals in his field, including Lei Miao and He Tian. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.

Conclusion

Ying Tang's contributions to pharmaceutical compositions exemplify the impact of innovation in medicine. His work continues to influence the development of effective treatments, showcasing the importance of research and collaboration in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…